Author:
Salah Husam M.,Al'Aref Subhi J.,Khan Muhammad Shahzeb,Al-Hawwas Malek,Vallurupalli Srikanth,Mehta Jawahar L.,Mounsey J Paul,Greene Stephen J.,McGuire Darren K.,Lopes Renato D.,Fudim Marat
Subject
Cardiology and Cardiovascular Medicine
Reference39 articles.
1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019
3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017
4. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019
5. v, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019